Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: Dosing strategy optimization

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5714-5716

  Andes, David R ^a   Reynolds, Daniel K ^b   Van Wart, Scott A ^b   Lepak, Alexander J ^a   Kovanda, Laura L ^c   Bhavnani, Sujata M ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECHINOCANDIN; MICAFUNGIN;

AREA UNDER THE CURVE; ARTICLE; DRUG DOSE COMPARISON; DRUG EFFICACY; ESOPHAGUS CANDIDIASIS; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID PHASE EXTRACTION; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; AREA UNDER CURVE; CANDIDA; CANDIDIASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ECHINOCANDINS; ESOPHAGUS; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 84885930028     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01057-13     Document Type: Article

References (29)

1. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
2. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
3. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. 2007. Back to the future: using aminoglycosides again and how to dose them optimally. Clin. Infect. Dis. 45:753-760.
4. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS, Jr. 1999. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gramnegative bacteria. Antimicrob. Agents Chemother. 43:623-629.
5. Lodise TP, Drusano GL. 2011. Pharmacokinetics and pharmacodynamics: optimal antimicrobial therapy in the intensive care unit. Crit. Care Clin. 27:1-18.
6. Lodise TP, Jr, Lomaestro B, Drusano GL. 2007. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin. Infect. Dis. 44:357-363.
7. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Lipman J. 2013. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin. Infect. Dis. 56: 236-244.
8. Ernst EJ, Roling EE, Petzold CR, Keele DJ, Klepser ME. 2002. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother. 46:3846-3853.
9. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. 2005. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother. 49:5058-5068.
10. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. 190:1464-1471.
11. Andes D. 2003. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47:1179-1186.
12. Andes D, Diekema DJ, Pfaller MA, Prince RA, Marchillo K, Ashbeck J, Hou J. 2008. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother. 52:539-550.
13. Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. 2010. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob. Agents Chemother. 54: 2497-2506.
14. Andes D, Marchillo K, Lowther J, Bryskier A, Stamstad T, Conklin R. 2003. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob. Agents Chemother. 47: 1187-1192.
15. Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J. 2008. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother. 52:3497-3503.
16. Lepak A, Castanheira M, Diekema D, Pfaller M, Andes D. 2012. Optimizing echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against C. glabrata with and without Fks mutations. Antimicrob. Agents Chemother. 56:5875-5882.
17. Gumbo T, Drusano GL, Liu W, Kulawy RW, Fregeau C, Hsu V, Louie A. 2007. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob. Agents Chemother. 51:968-974.
18. Petraitis V, Petraitiene R, Groll AH, Sein T, Schaufele RL, Lyman CA, Francesconi A, Bacher J, Piscitelli SC, Walsh TJ. 2001. Dosagedependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. 45:471-479.
19. de Wet NT, Bester AJ, Viljoen JJ, Filho F, Suleiman JM, Ticona E, Llanos EA, Fisco C, Lau W, Buell D. 2005. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment. Pharmacol. Ther. 21:899-907.
20. Niwa T, Yokota Y, Tokunaga A, Yamato Y, Kagayama A, Fujiwara T, Hatakeyama J, Anezaki M, Ohtsuka Y, Takagi A. 2004. Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol. Pharm. Bull. 27:1154-1156.
21. Hebert MF, Blough DK, Townsend RW, Allison M, Buell D, Keirns J, Bekersky I. 2005. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. 45:1018-1024.
22. Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, Bekersky I. 2005. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol. 45:1145-1152.
23. Hirata K, Aoyama T, Matsumoto Y, Ogawa F, Yamazaki H, Kikuti A, Yamamoto Y. 2007. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi 127:897-901.
24. Nakagawa Y, Ichii Y, Saeki Y, Kodaka M, Suzuki K, Kishino S. 2007. Plasma concentration of micafungin in patients with hematologic malignancies. J. Infect. Chemother. 13:39-45.
25. Van Wart S. 2008. Population pharmacokinetics of micafungin in patients with invasive candidiasis, candidemia and esophageal candidiasis, abstr A-011. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington DC.
26. Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL. 2008. Population pharmacokinetics of micafungin in adult patients. Diagn. Microbiol. Infect. Dis. 60:329-331.
27. Tabata K, Katashima M, Kawamura A, Tanigawara Y, Sunagawa K. 2006. Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. Biol. Pharm. Bull. 29: 1706-1711.
28. Sirohi B, Powles RL, Chopra R, Russell N, Byrne JL, Prentice HG, Potter M, Koblinger S. 2006. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant. 38: 47-51.
29. Hiemenz J, Cagnoni P, Simpson D, Devine S, Chao N, Keirns J, Lau W, Facklam D, Buell D. 2005. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob. Agents Chemother. 49:1331-1336.